CD274 and small cell lung carcinoma: Neither PD-L1 expression nor TMB status were found to be associated with OS or progression-free survival in patients with ES-SCLC treated with durvalumab or in long-term survival among patients with ES-SCLC treated with atezolizumab (56, 57).